Kadans Science, a company involved in investing in the development of ecosystems, will add Harrow House in Oxford, UK to its Pan-European portfolio. The asset will be acquired from Oxford Biomedica in a sale and lease back transaction. Harrow House is a purpose-built manufacturing facility which will be leased back, in its entirety, to Oxford Biomedica. Oxford Biomedica is an innovation-led viral vector contract development and manufacturing organization (CDMO), providing development and manufacturing expertise to pharmaceutical and biotechnology companies.

With the acquisition of Harrow House, Oxford, the Kadans portfolio now comprises of over 65 buildings and numerous projects under development in the Netherlands, United Kingdom, Germany, Belgium, France, and Spain. Kadans aspires to partner with universities, venture capital firms and innovative organizations to create one strong knowledge-sharing ecosystem of scientific enterprise across Europe.

James Sheppard, managing director (UK & Ireland) said, ‘We are pleased to be continuing to build our relationship with Oxford Biomedica. Harrow House has long played an important role for Oxford Biomedica and we look forward to working with them on the next stage of its evolution.’

Nick Page, chief operations officer at Oxford Biomedica said, “We welcome this opportunity to broaden our ongoing relationship with Kadans. This transaction enables us to maximize value from our earlier investment and assists with future growth opportunities as we build our position as a quality and innovation-led viral vector CDMO.